Low-dose empagliflozin as adjunct-to-insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy.
Perkins BA, Soleymanlou N, Rosenstock J, Skyler JS, Laffel LM, Liesenfeld KH, Neubacher D, Riggs MM, Johnston CK, Eudy-Byrne RJ, Elmokadem A, George JT, Marquard J, Nock V.
Perkins BA, et al. Among authors: neubacher d.
Diabetes Obes Metab. 2020 Mar;22(3):427-433. doi: 10.1111/dom.13945. Epub 2020 Jan 21.
Diabetes Obes Metab. 2020.
PMID: 31858718
Free PMC article.